Organization
Modulation Therapeutics
1 clinical trial
1 abstract
Clinical trial
First in Human Phase I Study of 225Actinium-MTI-201 (225Ac-MTI-201) in Metastatic Uveal MelanomaStatus: Recruiting, Estimated PCD: 2025-04-25
Abstract
First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM).Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine in St Louis, Modulation Therapeutics,